The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1b study of Plk1 inhibitor onvansertib in combination with paclitaxel in metastatic triple-negative breast cancer (mTNBC) patients.
 
Antonio Giordano
Consulting or Advisory Role - Pfizer; Pfizer; Pfizer; Pfizer
Research Funding - Cardiff Oncology (Inst)
Travel, Accommodations, Expenses - Pfizer
 
Qingchun Jin
No Relationships to Disclose
 
Eileen Wrabel
No Relationships to Disclose
 
Raechel Davis
No Relationships to Disclose
 
Alexander Schubert
No Relationships to Disclose
 
Michael Stalteri
Employment - Dana-Farber Cancer Institute
 
Zachary Smolar
No Relationships to Disclose
 
Sarah Sammons
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Foundation Medicine; Incyclix Bio; Loxo/Lilly; Novartis; Pfizer; Relay Therapeutics; Sermonix Pharmaceuticals
Research Funding - AstraZeneca/MedImmune (Inst); Lilly (Inst); Relay Therapeutics (Inst); Relay Therapeutics (Inst); Seagen (Inst); Sermonix Pharmaceuticals (Inst)
 
Nancy Lin
Stock and Other Ownership Interests - Artera
Consulting or Advisory Role - Artera; AstraZeneca; Blueprint Medicines; Daiichi Sankyo; Eisai; Johnson & Johnson/Janssen; Menarini; Olema Pharmaceuticals; Pfizer; Seagen
Research Funding - Genentech (Inst); Merck (Inst); Olema Pharmaceuticals (Inst); Pfizer (Inst); Seagen (Inst); Zion Pharma (Inst)
Patents, Royalties, Other Intellectual Property - Royalties for chapter in Up-to-Date regarding management of breast cancer brain metastases; Royalties, Jones & Bartlett
Travel, Accommodations, Expenses - AstraZeneca; Olema Pharmaceuticals
 
Kristina Fanucci
No Relationships to Disclose
 
Filipa Lynce
Leadership - Alliance Foundation Trials
Consulting or Advisory Role - AmerisourceBergen; AstraZeneca; Daiichi Sankyo/Astra Zeneca; Lilly; Pfizer; Prime Education
Research Funding - AstraZeneca/Daiichi Sankyo (Inst); Gilead Sciences; IDEAYA Biosciences; Incyte; Merck; Zentalis
 
Adrienne Waks
Consulting or Advisory Role - AstraZeneca
Research Funding - Genentech (Inst); Gilead Sciences (Inst); MacroGenics (Inst); Merck (Inst)
 
Maya Ridinger
Employment - Cardiff Oncology
Stock and Other Ownership Interests - Cardiff Oncology
Patents, Royalties, Other Intellectual Property - Cardiff Oncology Inc.
 
Erica Mayer
Consulting or Advisory Role - AstraZeneca; Lilly; Novartis
 
Fairooz Kabbinavar
Employment - Cardiff Oncology
Stock and Other Ownership Interests - Cardiff Oncology
 
Stephen Ethier
No Relationships to Disclose
 
Nabihah Tayob
No Relationships to Disclose
 
Geoffrey Shapiro
Consulting or Advisory Role - Bicycle Therapeutics; Merck Serono; Xinthera
Research Funding - Bristol-Myers Squibb/Medarex (Inst); Lilly (Inst); Merck (Inst); Merck Serono (Inst); Pfizer (Inst); Tango Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Patent # 10,934,593 B2 Compositions and methods for predicting response and resistance to CDK4/6 inhibition; Patent #: 9872874 Title: Dosage regimen for sapacitabine and seliciclib Issue Date: 1/23/2018
 
Steven Isakoff
Employment - Merus (I)
Stock and Other Ownership Interests - Merus NV (I)
Consulting or Advisory Role - Veracyte
Research Funding - Abbvie (Inst); AstraZeneca/MedImmune (Inst); Genentech (Inst); Merck (Inst); OncoPep (Inst)
 
Sara Tolaney
Consulting or Advisory Role - AADi; Ambrx; Artios Biopharmaceuticals; Arvinas; AstraZeneca; Bayer; BeiGene; Bicycle Therapeutics; BioNTech; Blueprint Medicines; Bristol-Myers Squibb; Circle Pharma; Cullinan Oncology; Daiichi Sankyo; eFFECTOR Therapeutics; Eisai; Genentech; Hengrui Pharmaceutical (USA); Immunomedics/Gilead; Incyte; Jazz Pharmaceuticals; Johnson & Johnson; Launch Therapeutics; Lilly; Menarini Group; Merck; Mersana; Natera; Novartis; Pfizer; Reveal Genomics; Sanofi; Seagen; Sumitovant Biopharma; Summit Therapeutics; Systimmune; Tango Therapeutics; Zentalis; Zuellig Pharma; Zymeworks
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo; Eisai (Inst); Exelixis (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Jazz Pharmaceuticals (Inst); Lilly (Inst); Menarini/Stemlin (Inst); Merck (Inst); NanoString Technologies (Inst); Novartis (Inst); OncoPep (Inst); Pfizer (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Arvinas; Gilead Sciences; Jazz Pharmaceuticals; Lilly; Pfizer; Sanofi
(OPTIONAL) Uncompensated Relationships - AstraZeneca; Gilead Sciences